BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35832830)

  • 1. Pathologic Complete Response Prediction to Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Real-World Evidence from Integrative Inflammatory and Nutritional Scores.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    J Inflamm Res; 2022; 15():3783-3796. PubMed ID: 35832830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Predictor of Pathologic Complete Response for Neoadjuvant Immunochemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma.
    Yang Y; Xin D; Wang H; Guan L; Meng X; Lu T; Bai X; Wang F
    J Inflamm Res; 2023; 16():1443-1455. PubMed ID: 37042015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic prediction by a novel integrative inflammatory and nutritional score based on least absolute shrinkage and selection operator in esophageal squamous cell carcinoma.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Front Nutr; 2022; 9():966518. PubMed ID: 36438741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of systemic immune-inflammation index for pathological complete response in patients receiving neoadjuvant immunochemotherapy for locally advanced esophageal cancer.
    Han W; Weng K; Zhang P; Hong Z
    Front Surg; 2022; 9():1091601. PubMed ID: 36684142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: A real-world study.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Biomol Biomed; 2023 Feb; 23(1):153-160. PubMed ID: 35880397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
    Xu L; Wei XF; Li CJ; Yang ZY; Yu YK; Li HM; Xie HN; Yang YF; Jing WW; Wang Z; Kang XZ; Zhang RX; Qin JJ; Xue LY; Bi N; Chen XK; Li Y
    Front Immunol; 2022; 13():1052542. PubMed ID: 36466925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study.
    Zhang H; Zhang Z; Yang L; Wu B; Chen Y; He H; Li C; Lin W; Lin J
    J Thorac Dis; 2023 Mar; 15(3):1279-1288. PubMed ID: 37065590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The usefulness of pretreatment controlling nutritional status score for predicting recurrence in patients with esophageal squamous cell carcinoma undergoing neoadjuvant immunochemotherapy: A real-world study.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Front Immunol; 2022; 13():1015365. PubMed ID: 36505443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combined nomogram based on radiomics and hematology to predict the pathological complete response of neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
    Yang Y; Yi Y; Wang Z; Li S; Zhang B; Sang Z; Zhang L; Cao Q; Li B
    BMC Cancer; 2024 Apr; 24(1):460. PubMed ID: 38609892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study.
    Zhao J; Hao S; Tian J; Li Y; Han D
    J Inflamm Res; 2023; 16():3351-3363. PubMed ID: 37576156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel immune-nutritional score predicts response to neoadjuvant immunochemotherapy after minimally invasive esophagectomy for esophageal squamous cell carcinoma.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Front Immunol; 2023; 14():1217967. PubMed ID: 37954582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis.
    He W; Wang C; Li C; Nie X; Li H; Li J; Zhao N; Chen H; Miao X; Han Y; Peng L; Leng X
    Front Immunol; 2023; 14():1118902. PubMed ID: 36875107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional neoadjuvant immunotherapy does not increase the risk of anastomotic leakage after esophagectomy for esophageal squamous cell carcinoma: a multicenter retrospective cohort study.
    Hong Z; Xu J; Chen Z; Xu H; Huang Z; Weng K; Cai J; Ke S; Chen S; Xie J; Duan H; Kang M
    Int J Surg; 2023 Aug; 109(8):2168-2178. PubMed ID: 37318861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of efficacy and safety between neoadjuvant chemotherapy and neoadjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.
    Xu J; Cai Y; Hong Z; Duan H; Ke S
    Int J Surg; 2024 Jan; 110(1):490-506. PubMed ID: 37800587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Feasibility of Esophagectomy Following Combined Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Analysis.
    Hong ZN; Gao L; Weng K; Huang Z; Han W; Kang M
    Front Immunol; 2022; 13():836338. PubMed ID: 35300335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1).
    Zhang Z; Hong ZN; Xie S; Lin W; Lin Y; Zhu J; Yang X; Lin Z; Lin J; Kang M
    Ann Transl Med; 2021 Nov; 9(21):1623. PubMed ID: 34926667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment Pan-Immune-Inflammation Value (PIV) in Predicting Therapeutic Response and Clinical Outcomes of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Ann Surg Oncol; 2024 Jan; 31(1):272-283. PubMed ID: 37838648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive nutritional index predicts clinical outcomes for esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Int Immunopharmacol; 2023 Aug; 121():110459. PubMed ID: 37307758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive nomogram for postoperative atrial fibrillation in locally advanced esophageal squamous carcinoma cell with neoadjuvant treatment.
    Fang M; Chen M; Du X; Chen S
    Front Surg; 2022; 9():1089930. PubMed ID: 36684273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
    Ruan Y; Ma Y; Ma M; Liu C; Su D; Guan X; Yang R; Wang H; Li T; Zhou Y; Ma J; Zhang Y
    J Transl Med; 2024 May; 22(1):471. PubMed ID: 38762454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.